Literature DB >> 23666369

miR-155-deficient bone marrow promotes tumor metastasis.

Fang Yu1, Xuemei Jia, Fen Du, Junfeng Wang, Yuzhen Wang, Walden Ai, Daping Fan.   

Abstract

UNLABELLED: Infiltration of immune cells in primary tumors and metastatic sites is known to influence tumor progression and metastasis. Macrophages represent the most abundant immune cells in the tumor microenvironment, and evidence has shown that macrophages promote seeding, extravasation, and persistent growth of tumor cells at metastatic sites. miR-155 plays an essential role in immune cell development/function, and its aberrant expression is associated with lymphomas and several solid tumor types. However, it is unknown how miR-155 expression in immune cells affects solid tumor growth and metastasis. To this end, bone marrow transplantation was performed using miR-155-deficient mice as bone marrow donors and wild-type (WT) mice as recipients, and the chimeric mice were inoculated with tumor cells. We demonstrate that bone marrow lacking miR-155 significantly enhanced lung metastasis without a substantial effect on primary tumor growth. Relative to mice with WT bone marrow, miR-155-deficient bone marrow accumulated more macrophages in the spleen and lungs. Further analysis revealed that miR-155-deficient macrophages in metastatic sites exhibited a tumor-promoting M2 phenotype. In vitro study suggested that miR-155-null macrophages were prone to M2 polarization upon incubation with tumor cell-conditioned medium, due to elevated expression of C/EBPβ, an identified miR-155 target. These data, for the first time, demonstrate that miR-155 in host immune cells plays a vital role in modulating solid tumor metastasis by affecting the recruitment and polarization of bone marrow-derived macrophages. IMPLICATIONS: Targeted inhibition of miR-155 delays tumor development but inhibition in host immune cells may encourage metastasis. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666369      PMCID: PMC3748167          DOI: 10.1158/1541-7786.MCR-12-0686

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  52 in total

1.  High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma.

Authors:  Anke van den Berg; Bart-Jan Kroesen; Klaas Kooistra; Debora de Jong; Jane Briggs; Tjasso Blokzijl; Susan Jacobs; Joost Kluiver; Arjan Diepstra; Ewerton Maggio; Sibrand Poppema
Journal:  Genes Chromosomes Cancer       Date:  2003-05       Impact factor: 5.006

2.  T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC.

Authors:  Deanna Haasch; Yung-Wu Chen; Regina M Reilly; X Grace Chiou; Sandra Koterski; Morey L Smith; Paul Kroeger; Kerri McWeeny; Donald N Halbert; Karl W Mollison; Stevan W Djuric; James M Trevillyan
Journal:  Cell Immunol       Date:  2002 May-Jun       Impact factor: 4.868

Review 3.  The many faces of macrophage activation.

Authors:  David M Mosser
Journal:  J Leukoc Biol       Date:  2003-02       Impact factor: 4.962

4.  The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages.

Authors:  Shanjin Cao; Jianguo Liu; Lihua Song; Xiaojing Ma
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

5.  Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155.

Authors:  Xing Cai; Yuan Yin; Ningzhu Li; Dihan Zhu; Junfeng Zhang; Chen-Yu Zhang; Ke Zen
Journal:  J Mol Cell Biol       Date:  2012-07-24       Impact factor: 6.216

6.  BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.

Authors:  Joost Kluiver; Sibrand Poppema; Debora de Jong; Tjasso Blokzijl; Geert Harms; Susan Jacobs; Bart-Jan Kroesen; Anke van den Berg
Journal:  J Pathol       Date:  2005-10       Impact factor: 7.996

7.  Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta.

Authors:  Michael J Gray; Mirjana Poljakovic; Diane Kepka-Lenhart; Sidney M Morris
Journal:  Gene       Date:  2005-06-20       Impact factor: 3.688

8.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas.

Authors:  Peggy S Eis; Wayne Tam; Liping Sun; Amy Chadburn; Zongdong Li; Mario F Gomez; Elsebet Lund; James E Dahlberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

9.  The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4.

Authors:  I C Ho; M R Hodge; J W Rooney; L H Glimcher
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

Review 10.  The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.

Authors:  L Bingle; N J Brown; Claire E Lewis
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

View more
  23 in total

1.  Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.

Authors:  James V Michael; Jeremy G T Wurtzel; Guang Fen Mao; A Koneti Rao; Mikhail A Kolpakov; Abdelkarim Sabri; Nicholas E Hoffman; Sudarsan Rajan; Dhanendra Tomar; Muniswamy Madesh; Marvin T Nieman; Johnny Yu; Leonard C Edelstein; Jesse W Rowley; Andrew S Weyrich; Lawrence E Goldfinger
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

2.  MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice.

Authors:  Fen Du; Fang Yu; Yuzhen Wang; Yvonne Hui; Kevin Carnevale; Mingui Fu; Hong Lu; Daping Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

3.  Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.

Authors:  Xuemei Jia; Fang Yu; Junfeng Wang; Stephen Iwanowycz; Fatma Saaoud; Yuzhen Wang; Jun Hu; Qian Wang; Daping Fan
Journal:  Breast Cancer Res Treat       Date:  2014-10-14       Impact factor: 4.872

4.  MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.

Authors:  Junfeng Wang; Fang Yu; Xuemei Jia; Stephen Iwanowycz; Yuzhen Wang; Shiang Huang; Walden Ai; Daping Fan
Journal:  Int J Cancer       Date:  2014-08-30       Impact factor: 7.396

5.  Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Authors:  Thomas B Huffaker; Soh-Hyun Lee; William W Tang; Jared A Wallace; Margaret Alexander; Marah C Runtsch; Dane K Larsen; Jacob Thompson; Andrew G Ramstead; Warren P Voth; Ruozhen Hu; June L Round; Matthew A Williams; Ryan M O'Connell
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

Review 6.  OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer.

Authors:  Alexander A Svoronos; Donald M Engelman; Frank J Slack
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

7.  Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Authors:  Siqi Chen; Long Wang; Jie Fan; Cong Ye; Donye Dominguez; Yi Zhang; Tyler J Curiel; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Res       Date:  2014-12-10       Impact factor: 12.701

Review 8.  MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response.

Authors:  Kobina Essandoh; Yutian Li; Jiuzhou Huo; Guo-Chang Fan
Journal:  Shock       Date:  2016-08       Impact factor: 3.454

9.  Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma.

Authors:  Yan-Li Qu; Hai-Feng Wang; Zhen-Qiang Sun; Yong Tang; Xiao-Na Han; Xian-Bo Yu; Kun Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.

Authors:  Muhammad Tariq; Jie-Qiong Zhang; Gui-Kai Liang; Qiao-Jun He; Ling Ding; Bo Yang
Journal:  Acta Pharmacol Sin       Date:  2017-10-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.